Objective: Osteoarthritis (OA) is the most common type of arthritis and causes debilitating 24 symptoms and decreased quality of life. Currently available treatment options target symptoms but 25 do not address the underlying issue of joint tissue degeneration. As such, a better understanding of 26 the molecular mechanisms maintaining cartilage health is needed for developing novel therapeutic 27 strategies. Liver X Receptors (LXRs) are nuclear receptors that have been previously shown to 28 offer protection against OA. This is potentially due to suppression of chondrocyte hypertrophy in 29 endochondral bone growth in response to LXR activation. In order to better understand the 30 regulatory mechanisms behind this effect, we aimed to systematically examine LXR's effects on 31 growth plate chondrocyte gene expression. 32
responsible for cellular cholesterol efflux. This provides insight into potential mechanisms through 47 which LXR regulates cellular metabolism to alter chondrocyte behavior and phenotype. 48 Introduction 66 Osteoarthritis (OA) is a prevalent degenerative joint disease that globally affects 10% of men and 67 18% of women over the age of 60 (1,2). Currently available treatment options merely alleviate 68 symptoms and attempt to improve function through approaches such as joint replacement surgery, 69 but do not address the underlying cause (3). Thus, there is an urgent need for a better understanding 70 of the cellular and molecular mechanisms that contribute to the pathogenesis of OA. Osteoarthritis 71 is a multifactorial disease with a complex causative and progressive process. The contributing 72 sources to the pathophysiology of primary OA include age, genetics, gender, weight and 73 metabolism, whereas secondary OA is primarily attributed to joint injury (4,5). Although OA may 74 affect tissues of the entire joint, the characterizing feature of OA is the progressive loss of the 75 structure and function of the articular cartilage (5,6). Cartilage degradation in OA is generally due 76 to the loss of the balance between synthesis and degradation of the extracellular matrix (ECM) 77 responsible for maintaining cartilage homeostasis and function, and changes in chondrocyte 78 phenotype also contribute to this pathology (5, 7, 8) . 79 80 Certain cellular and molecular events in endochondral bone formation have been found to be 81 recapitulated in OA pathogenesis, where disruptions of chondrogenic differentiation can lead to 82 the onset of OA (9). In particular, ectopic chondrocyte hypertrophy within the articular cartilage 83 has been shown to act as an OA-promoting factor (9-11). This is demonstrated by protection 84 against injury-induced OA in mice lacking drivers of chondrocyte hypertrophy such as Runx2 or 85
Hif2α (12-14). It remains unclear whether it is chondrocyte hypertrophy itself, or simply the 86 induction of hypertrophy-associated genes, or the combination of both that contributes to cartilage 87 degeneration in OA (15). Nevertheless, the differentiation and phenotypic changes that developing 88 growth plate chondrocytes undergo are usually resisted in healthy articular chondrocytes, allowing 89 for a stable and permanent structure for joint articulation (16 showed LXR activation to suppress chondrocyte hypertrophy during endochondral bone growth, 101 formulating a novel potential underlying mechanism of LXR's protection against OA (23). 102
However, the signaling pathways and target genes mediating this suppression remain to be 103 elucidated. 104
105
The objective of this study was to identify target genes of LXR in developing growth plate 106 chondrocytes. We performed microarray analyses on RNA extracted from primary chondrocytes 107 isolated from embryonic day 15.5 (E15.5) mouse long bones treated with or without an LXR 108 agonist. Differentially regulated genes were subsequently validated at both the mRNA and protein 109 level, where we show changes in gene expression after LXR agonist treatment to primarily affect 110 lipid metabolism. We also show for the first time LXR's ability to regulate target protein 111 Primary chondrocytes were isolated from long bones of E15.5 CD1 mice (femur, tibia, radius, 149 ulna, fibula, humerus, scapula) and cultured as previously described with modifications (24). To 150 remove muscle and other associated tissue, isolated long bones were subjected to a 15 minute 151 incubation in 500 µL of trypsin at 37°C under agitation. This was followed by a 1.5-2 hour 152 incubation in Collagenase-P (3 mg/mL, Roche) diluted in Dulbecco's Modified Eagles Medium 153 (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2. Digested cells were strained with a 40 µm cell strainer, then plated on 1.2% agarose. Cells were allowed to 155 recover overnight before commencement of treatment using DMSO as vehicle control, or GW3965 156 at 1 µM concentration for a period of 24 hours. 157 158 RNA isolation and microarray analyses 159 Following treatment, RNA was isolated from primary chondrocytes using TRIzolä (Invitrogen) 160 as per manufacturer's instructions and as previously described (19) . In brief, cell homogenization 161 with TRIzolä was followed by the addition of chloroform for phase separation and the upper 162 aqueous phase was removed. RNA was precipitated using 100% isopropanol and washed with 163 70% ethanol. RNA was allowed to air-dry prior to resuspension in RNAse-free water, then 164 quantified using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). RNA integrity 165 was determined using the Agilent 2100 Bioanalyzer, and samples with RNA integrity number 166 (RIN) greater than 8 were used for microarray analyses at the London Regional Genomics Centre, 167
Robarts Institute (London, ON, Canada). Array (Thermo Fisher Scientific) containing probe sets representing > 28,000 coding transcripts, 172 as previously described (19). The complete microarray data set will be deposited at the publicly 173 accessible Gene Expression Omnibus (GEO) database, and NCBI accession number provided. Pathology Core Facility, Robarts Institute (London, ON, Canada). Immunohistochemistry was 202 conducted as described with minor modifications (19,23). Paraffin sections were dewaxed and 203 carried through a series of rehydration steps, followed by incubation in 3% H2O2. Antigen retrieval 204 was performed with 0.1% Triton X-100 for 11 minutes, then slides were blocked with 5% goat 205 serum in PBS, and incubated overnight at 4°C with primary antibodies against LXRa/b (sc-206 377260, Santa Cruz Biotechnology), Abca1 (PA1-16789, Thermo Fischer Scientific), or Srebp1 207 (PA1-337, Thermo Fischer Scientific). Secondary antibody incubation was followed by 208 Our laboratory previously reported LXR activation through GW3965 treatment to result in delayed 228 chondrocyte hypertrophy in endochondral bone growth (23). In order to further understand the 229 regulatory role of LXR in chondrocyte hypertrophy and growth plate development, we performed 230 microarray analyses for differential gene expression in E15 primary chondrocytes treated with or 231 without the LXR specific agonist, GW3965, for a period of 24 hours. Expression of 30 annotated 232 genes was found to be significantly changed in response to LXR activation, with 7 genes down-233 regulated and 23 genes up-regulated (Supplementary Table 2 ). In order to gain a better understanding of the potential roles of these differentially regulated genes, 244
we conducted Gene Ontology and KEGG pathway analyses. This allows for the identification of 245 represented cellular components, molecular functions, and biological processes, as well as 246 associated pathways. The top 10 gene ontology groups prioritized by enrichment scores are 247 primarily biological processes involved in lipid metabolism, including cholesterol metabolic process, lipoprotein metabolic process, and plasma lipoprotein particle organization [ Fig. 1(b) ]. 249
Similarly, the top 10 KEGG pathways prioritized by enrichment scores indicate differentially 250 regulated genes to be represented in various pathways of lipid homeostasis, including fatty acid 251 metabolism, peroxisome proliferator-activated receptor (PPAR) signaling pathway, and 252 adipocytokine signaling pathway [ Fig. 1(c) ]. Collectively, these analyses suggest the primary 253 effect of LXR activation in growth plate chondrocytes to be control of cellular lipid homeostasis. Positive staining of Abca1 was observed to be localized to the nucleus, the perinuclear area, and 291 the cytoplasm [Fig 5(a) ]. In contrast, subcellular localization of Srebp1 appears to be mainly 292 nuclear [ Fig. 5(b) ]. Examination of differentially regulated lipid metabolic genes showed Abca1, 293
Abcg1, Scd1, Lpcat3, and Acsl3 to be significantly up-regulated by GW3965 throughout 294 chondrocyte differentiation in micromass culture, but most markedly so during terminal chondrocyte differentiation [ Fig. 6 ]. While Srebp1 expression demonstrated a similar trend, its 296 upregulation in response to LXR activation did not reach statistical significance in this culture 297 system. Taken together, these findings suggest lipid metabolic targets of LXR to be regulated in a 298 similar manner as LXR upon LXR activation, where their expression appears to be highly 299 increased in pre-hypertrophic and hypertrophic chondrocytes. Previous studies have demonstrated LXR to play key functions in coordinating whole-body lipid 321 homeostasis through highly metabolically active tissues such as the liver (26,27). However, much 322 less is known regarding its roles in regulating lipid metabolism in cartilage. LXR's potential 323 therapeutic implications in OA has been clearly demonstrated by its chondroprotective effects in 324 cartilage and in suppressing hypertrophic differentiation of developing chondrocytes (21,23); 325 however, the underlying mechanisms behind these effects remain unknown. In the present study, 326
we performed microarray analysis to examine transcriptional regulation by LXR in growth plate plate, yet more localized to the pre-hypertrophic and resting zones upon activation with the LXR-366 specific agonist GW3965. Several studies in human macrophages and mouse adipose tissue have identified LXR response elements (LXRE) in the Lxra promoter, suggesting LXRs to possess 368 tissue-specific autoregulatory functions (45-47). Our study suggests for the first time that such 369 autoregulation exists in chondrocytes, where GW3965-treatment resulted in further preferential 370 activation of LXRa in pre-hypertrophic and resting chondrocytes. 371
372
The overlap in LXR target genes between primary growth plate chondrocytes and IMACs was 373 lower than expected. This could be due to cell type-specific effects, but changes in experimental 374 design could also contribute to these differences. In particular, growth plate chondrocytes were 375 incubated with GW3965 for 24 hours, while IMACs received the drug for 72 hours (19). Thus, 376 secondary or tertiary effects of LXR activation would only be seen in the IMAC system. 377
Nevertheless, the dominant biological process affected by LXR activation in both contexts was 378 lipid metabolism, and the genes showing strongest induction overlapped greatly. 379
380
In summary, our study shows for the first time that LXR activation by its specific synthetic agonist, 381 GW3965, differentially regulates genes involved in lipid metabolism in growth plate chondrocytes. 382
Specifically, the LXR-Srebp1-Scd1 axis was identified to be a potential mechanism employed by 383 LXR to maintain cellular cholesterol homeostasis. Further studies are needed to functionally 384 validate these lipid metabolic changes in response to LXR activation in both the normal and 385 
